



**Donate
now**

January 2022



Dear friends of the Agency,

I wish each of you and your families **a very happy New Year 2022!**

2021 drew to a close with some important strategic meetings with IARC's partners and the World Health Organization (WHO). On 14 October 2021, I met in Lyon with the Executive Director of the WHO Academy, Professor Agnès Buzyn, and had a fruitful discussion about the possibility for IARC and the WHO Academy to share resources and services in IARC's new headquarters, the Nouveau Centre building.

On 12 November 2021, IARC coordinated a high-level meeting between the Agency and WHO. The meeting was an opportunity to improve and accelerate coordination between IARC and WHO, and the outcome will be a collaborative work plan for 2022-2023 in line with both the WHO Thirteenth General Programme of Work 2019-2023 and the IARC Medium-Term Strategy 2021-2025.

The recently published **IARC Biennial Report 2020-2021** showcases a selection of the work conducted by IARC with its global network of experts. **Key cancer data and key figures on IARC during the 2020-2021 biennium** also illustrate IARC's fundamental research priorities in a companion webpage.

In 2022, IARC will embark on an exciting new phase in its history with the implementation of its scientific strategy and the exciting move to the Nouveau Centre. Starting with the Fifty-eighth Session of the IARC Scientific Council, to be held by webconference on 9-11 February, 2022 will be an important year for IARC.

I look forward to continuing IARC's essential mission in cancer prevention research, and working to achieve a world where fewer people develop cancer.

Best regards,

Dr Elisabete Weiderpass
IARC Director




Visit of delegation from Special Committee on Beating Cancer

[Read more](#)



Third annual IAEA-IARC-WHO consultation

[Read more](#)




Launch of Cancer Over Time on IARC Global Cancer Observatory website: exploring cancer trends worldwide

[Read more](#)



Cancer Prevention Europe launches second part of multilingual learning programme on cancer prevention

[Read more](#)



The relative and attributable risks of cardia and non-cardia gastric cancer associated with *Helicobacter pylori* infection in China: a case-cohort study

[Read more](#)



Co-benefits from sustainable dietary shifts for population and environmental health: an assessment from a large European cohort study

[Read more](#)


- Evidence Synthesis and Classification

IARC celebrates 50 years of the *IARC Monographs*



The unveiling of the 50th anniversary logo and the release of the **inaugural issue of the *IARC Monographs* newsletter** are auspiciously timed for the anniversary of the first *IARC Monographs* meeting, which took place on 13-17 December 1971. During 2022, IARC will celebrate this milestone with several events, including a photo exhibition and a scientific workshop, and special-edition anniversary merchandise will be available. To join the celebrations and stay informed, **subscribe to the *IARC Monographs* newsletter**.


[Read more](#)



IARC Monographs Volume 128: Acrolein, Crotonaldehyde, and Arecoline

A Working Group of **international experts**, including 20 scientists from 10 countries, reviewed evidence from cancer in humans, cancer bioassays in experimental animals, and mechanistic studies to assess the carcinogenic hazard to humans of exposure to acrolein, crotonaldehyde, and arecoline. The outcome of the assessment has been published in a **summary article** in *The Lancet Oncology* and is described in detail in **Volume 128 of the *IARC Monographs***, which is now available online.


[Read more](#)



IARC Handbooks of Cancer Prevention Volume 18: Evaluation of cervical cancer screening methods

An international Working Group of 27 expert scientists from 18 countries reviewed and assessed all available evidence on current methods for cervical cancer screening in terms of their effectiveness in reducing cervical cancer incidence and mortality. A **Special Report**, published in *The New England Journal of Medicine*, presents the evaluations and other conclusions of the Working Group. The detailed assessments will be published in 2022 as Volume 18 of the *IARC Handbooks of Cancer Prevention*.

[Read more](#)



WHO Classification of Tumours: Central Nervous System Tumours, 5th Edition, Volume 6

The *WHO Classification of Tumours* series, also known as the WHO Blue Books, is regarded as the reference standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. Its content is also available in a convenient **online format by subscription**. Central Nervous System Tumours is the sixth volume in the 5th edition of the WHO series.

[Read more](#)




World Cancer Report Updates webinar: Challenges and Opportunities for Primary Cancer Prevention: In the **fifth World Cancer Report Updates webinar**, chaired by Dr Béatrice Lauby-Secretan, Deputy Head of the Evidence Synthesis and Classification Branch, two speakers presented an overview of the modifiable cancer risk factors and cancer prevention perspectives.

[Visit the learning platform](#)



The International Collaboration for Cancer Classification and Research (IC³R): IARC, with international partners, has established the IC³R to promote evidence-based practice and standards for cancer classification and research. IC³R provides a forum to coordinate evidence generation, synthesis, evaluation, and standard-setting for tumour classification worldwide.

[Read more](#)



Updated Monographs classification by organ site: The **updated list of classifications by cancer site** indicates all the tumour sites in listing the agents for which there is *sufficient* or *limited evidence* in humans. The **organ site poster**, available in five languages, illustrates the carcinogenic agents and cancer-preventive interventions by organ or group of organs.

[Read more](#)

#cancerresearchthatmatters

[iarc who](#) [iarc who](#) [@iarcwho](#) [www.iarc.who.int](#)

Was this email forwarded to you?
Subscribe to our newsletter to stay informed

[Sign up now](#)

Copyright © 2022 International Agency for Research on Cancer, All rights reserved.

You are receiving this email because you have engaged with IARC in the past or because you opted in on our website.

Our mailing address is:
International Agency for Research on Cancer (IARC)
150 Cours Albert Thomas
Lyon 69008
France

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

Kindly note that the [WHO/IARC privacy policy](#) applies.